(Q35157640)

6 August 2017

1 reference

title

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia (English)

1 reference

6 August 2017

1 reference

Gerald L Andriole

1

1 reference

PubMed ID

12814679

6 August 2017

Roger Kirby

series ordinal

2

1 reference

PubMed ID

12814679

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

44

1 reference

6 August 2017

1

1 reference

6 August 2017

82-88

1 reference

Medical therapy for benign prostatic hyperplasia: a review of the literature

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

Recent advances in clinical/molecular andrology.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900198-2

7 January 2021

10.1016/S0302-2838(03)00198-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12814679